Skip to main content
TipRanks
Go Ultimate75% OFF

Zymeworks (ZYME) AI Stock Analysis

670 Followers
ZYME

Zymeworks

(NASDAQ:ZYME)

Select Model
Rating:48Neutral
Price Target:$26.00â–²(0.62% Upside)
Action:reiterated
Date:11/16/26

Overall score is held back primarily by weak cash flow (negative operating/free cash flow) and the sharp increase in debt, despite improved TTM profitability and revenue. Technicals are soft with the stock below key moving averages, while valuation remains elevated (P/E ~39) without dividend support. Corporate events are a relative positive (raised guidance, major partnership/milestone, and buyback), but they do not fully offset cash burn and leverage risk.

Positive Factors
Revenue and earnings recoveryThe sharp TTM revenue increase and return to positive net income and EBITDA show meaningful recent operating improvement. If sustained, this larger revenue base can support investment in the pipeline, improve operating leverage, and strengthen Zymeworks’ ability to fund growth.
Negative Factors
Persistent cash burnNegative operating and free cash flow indicate that reported earnings are not yet translating into internally generated cash. Continued burn can require external financing or milestone timing to support development, limiting flexibility and making financial sustainability more dependent on future cash inflows.

Zymeworks (ZYME) vs. SPDR S&P 500 ETF (SPY)

-10%0%10%20%30%40%ZYME+8.48%SPY+11.73%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$1.80B
Dividend Yield
―
Average Volume (3M)
1.04M
Price to Earnings (P/E)
38.3
Beta (1Y)
0.63
Revenue Growth
97.78%
EPS Growth
―
Country
US
Employees
279
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Zymeworks Business Overview & Revenue Model

Company Description

Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, advancing, and bringing to market biological therapies aimed at combating cancer. Its pipeline features two primary experimental treatments: zanid...

How the Company Makes Money

Zymeworks makes money primarily through (1) collaboration and licensing arrangements and (2) income related to its own product candidates, if and when they achieve regulatory approval and commercialization. Under collaboration/licensing deals, Zymewo...

Zymeworks Earnings Call Summary

Earnings Call Date:May 07, 2026(Q1-2026)|% Change Since:-2.86%|Next Earnings Date:Mar 10, 2027
Earnings Call SentimentNeutral

The call conveyed a mixed but cautiously constructive picture: strong scientific and clinical progress (notably the zanatumab regulatory milestones, compelling ZW191 Phase 1 efficacy signals, and an advancing pan‑RAS ADC preclinical platform) and a materially improved cash balance supported by active buybacks and potential milestone upside. Offsetting this, near‑term GAAP performance showed a sharp revenue decline (‑91.1% YoY) and a widened net loss (≈+95.6%), and the company remains dependent on partner milestones and exposed to ex‑U.S. pricing pressures. Pipeline timing risks (e.g., ZW1528 delayed to 2027) and the need for partnerships to scale certain programs temper the near‑term outlook, but management presented credible funding and strategic plans tied to milestones and disciplined capital allocation.

Positive Updates

Near-term Regulatory Catalysts for Zanatumab
PDUFA date set for 08/25/2026 in first-line GEA (U.S.) and sBLA filing completed in China, creating visible near-term commercialization pathway with partners Jazz and BeiGene and potential for meaningful milestone and royalty revenue.

Negative Updates

Sharp Revenue Decline Year-over-Year
Total revenue of $2.4M for Q1 2026 versus $27.1M in Q1 2025, a decline of approximately 91.1% YoY driven primarily by nonrecurring clinical milestones in 2025 and lower development support and drug supply revenue from Jazz.

Company Guidance

The company reiterated near-term regulatory and operational milestones, including a U.S. PDUFA date of 08/25/2026 and an sBLA filing in China for first-line GEA, with near-term approval-triggered milestone payments of $250.0 million (U.S.) and $15.0 million (China) and management citing $440.0 million of anticipated regulatory milestones (U.S./EU/Japan/China) that, together with $403.8 million of cash, cash equivalents and marketable securities as of 03/31/2026 (up from $270.6 million on 12/31/2025), they expect to fund operations beyond 2028 assuming full execution of the $125.0 million repurchase plan; Q1 2026 revenue was $2.4 million versus $27.1 million a year ago, operating expenses were $49.5 million (Q1 2026) versus $52.7 million, and net loss was $44.2 million versus $22.6 million, while share repurchases have used ~$95.8 million of the $125.0 million program to buy ~3.93 million shares at an average $24.37 (total repurchases since 2024 ~ $155.8M for ~8.3M shares at ~$18.70, >10% of shares), leaving ~73 million common shares outstanding; clinical and R&D guidance included ZW191 dose‑optimization (≈60‑patient cohort fully enrolled) with median follow‑up ~7 months, ovarian ORR 56% (>=30% shrinkage in 68%, any shrinkage in 85%, DCR 94%) and at 6.4–9.6 mg/kg ORR 61% with disease control in all patients, endometrial ORR 40% (>=30% shrinkage in 50%, any shrinkage in 70%, DCR 80%) rising to ORR 57% at 6.4–9.6 mg/kg, responses seen from 3.2 mg/kg, ZW1528 IND now guided to 2027 (vs prior 2026), pan‑RAS ADC preclinical program delivered >117 novel inhibitors, three candidate ADCs (ZW439, ZW427, ZW418) were presented at AACR, DAR‑8 format was used, and the lead RAS ADC showed NHP tolerability with no body‑weight, skin or GI toxicity up to 120 mg/kg; additional data cadence was guided toward oncology meetings in 2026 (including ESMO GYN in June).

Zymeworks Financial Statement Overview

Summary

Fundamentals are mixed: TTM revenue and net income improved (positive net income and EBITDA), but balance-sheet risk increased sharply with much higher total debt, and cash generation is weak with negative operating and free cash flow (ongoing cash burn).

Income Statement

56Neutral

Balance Sheet

38Negative

Cash Flow

34Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue265.97M105.97M76.30M76.01M412.48M26.68M
Gross Profit261.44M105.97M76.30M-66.98M412.48M26.68M
EBITDA57.08M-68.64M-108.62M-120.70M142.49M-206.09M
Net Income43.31M-81.13M-122.69M-118.67M124.34M-211.84M
Balance Sheet
Total Assets1.18B346.53M463.09M580.88M648.73M389.13M
Cash, Cash Equivalents and Short-Term Investments100.46M228.80M225.78M374.33M492.23M252.61M
Total Debt650.28M18.27M18.51M26.72M28.11M32.33M
Total Liabilities918.16M78.03M124.32M116.07M155.77M140.04M
Stockholders Equity258.25M268.50M338.77M464.81M492.96M249.09M
Cash Flow
Free Cash Flow-112.33M-34.53M-113.11M-122.38M130.98M-205.74M
Operating Cash Flow-111.69M-33.01M-110.04M-118.30M144.11M-192.45M
Investing Cash Flow-297.64M26.66M38.76M-207.25M-53.85M144.60M
Financing Cash Flow444.83M-18.56M-20.45M81.85M108.58M8.01M

Zymeworks Technical Analysis

Technical Analysis SentimentNegative
Last Price25.84

Price Trends

50DMA27.22Negative
100DMA26.40Negative
200DMA25.56Positive

Market Momentum

MACD-0.03Positive
RSI40.76Neutral
STOCH7.30Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ZYME, the sentiment is Negative. The current price of 25.84 is below the 20-day moving average (MA) of 28.65, below the 50-day MA of 27.22, and above the 200-day MA of 25.56, indicating a neutral trend. The MACD of -0.03 indicates Positive momentum. The RSI at 40.76 is Neutral, neither overbought nor oversold. The STOCH value of 7.30 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ZYME.

Zymeworks Risk Analysis

Zymeworks disclosed 73 risk factors in its most recent earnings report. Zymeworks reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

3 New Risks
1.Our business may be adversely affected if we do not successfully realize the anticipated benefits of our acquisition of Theravance.Q3, 2026
2.We and/or our collaboration partners and those commercializing products with respect to which we have an economic interest or right to receive royalties may face competition from companies seeking to market generic versions of any approved products in which we have an interest, such as YUPELRI.Q3, 2026
3.In collaboration with Viatris, we are responsible for marketing and sales of YUPELRI in the US, which subjects us to certain risks.Q3, 2026

Zymeworks Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

ZYME against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
VIRVIR68Neutral$1.58B-7.40-21.38%―1695.96%65.40%
ANABANAB61Neutral$1.36B7.14906.99%―13.04%―
XNCRXNCR61Neutral$2.59B-22.05-21.29%―33.55%11.51%
ABCLABCL57Neutral$3.60B-23.08-15.35%―92.10%16.43%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
ZYMEZYME48Neutral$1.80B38.3222.48%―97.78%―
GENBGENB42Neutral$1.27B-4.15-146.07%―――

* Healthcare Sector Average

Performance Comparison

0%100%200%300%ZYMEXNCRANABVIRABCLGENBDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
ZYME and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
ZYMEZymeworks25.843.2414.34%
XNCRXencor Inc.34.5018.73118.77%
ANABAnaptysBio45.6120.9484.89%
VIRVir Biotechnology, Inc.9.253.8170.04%
ABCLAbcellera Biologics, Inc.11.037.42205.54%
GENBGenerate Biomedicines, Inc.9.84-2.81-22.21%

Zymeworks Corporate Events

Stock Buyback

Zymeworks Authorizes New $200 Million Share Repurchase Program

Positive
Nov 16, 2026

Zymeworks is a global biotechnology company building a diversified portfolio of healthcare assets while advancing innovative medicines for difficult-to-treat diseases. Its portfolio includes YUPELRI, Ziihera and pasritamig, supported by internal rese...

Business Operations and StrategyFinancial DisclosuresM&A TransactionsProduct-Related Announcements

Zymeworks Reports Quarterly Results, Raises 2026 Guidance

Positive
Nov 9, 2026

On November 9, 2026, Zymeworks reported financial results for the quarter ended September 30, 2026, and raised its 2026 guidance. Total revenue guidance increased to $337 million-$351 million from $278 million-$292 million, while adjusted EBITDA guid...

Business Operations and StrategyPrivate Placements and Financing

Zymeworks Announces Global DLL3 T-Cell Engager Partnership

Positive
Oct 23, 2026

On October 22, 2026, Zymeworks entered into an exclusive global collaboration and license agreement with Roche for ZW209, its trispecific T-cell engager targeting DLL3-expressing tumor cells. The deal grants Roche worldwide rights to develop and comm...

Business Operations and StrategyM&A TransactionsPrivate Placements and Financing

Zymeworks Closes Theravance Acquisition and CVR Financing

Positive
Sep 23, 2026

On September 22, 2026, Zymeworks entered into a Contingent Value Rights Agreement in connection with its merger, granting former stakeholders non-tradeable rights tied to future monetization and commercialization of ampreloxetine over a 10-year perio...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 16, 2026